Larimar Therapeutics, Inc. (LRMR) Tops Q3 EPS by 13c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q3 EPS of ($0.24), $0.13 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• PreveCeutical closes second tranche of private placement for $245,000
• Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders